The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung
Abstract
The effects of a second generation p38 mitogen-activated protein kinase (MAPK) inhibitor, SB 239063 [ trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole; IC 50= 44 nM vs. p38α], were assessed in models that represent different pathological aspects of chronic obstructive pulmonary disease (COPD) [airway neutrophilia, enhanced cytokine formation and increased matrix metalloproteinase (MMP)-9 activity] and in a model of lung fibrosis. Airway neutrophil infiltration and interleukin (IL)-6 levels, assessed by bronchoalveolar lavage 48 h after lipopolysaccharide (LPS) inhalation, were inhibited dose dependently by 3–30 mg/kg of SB 239063 given orally twice a day. In addition, SB 239063 (30 mg/kg orally) attenuated IL-6 bronchoalveolar lavage fluid concentrations (>90% inhibition) and MMP-9 activity (64% inhibition) assessed 6 h after LPS exposure. In guinea pig cultured alveolar macrophages, SB 239063 inhibited LPS-induced IL-6 production (IC 50 of 362 nM). In a bleomycin-induced pulmonary fibrosis model in rats, treatment with SB 239063 (2.4 or 4.8 mg/day via osmotic pump) significantly inhibited bleomycin-induced right ventricular hypertrophy (indicative of secondary pulmonary hypertension) and increases in lung hydroxyproline synthesis (indicative of collagen synthesis and fibrosis). Therefore, SB 239063 demonstrates activity against a range of sequelae commonly associated with COPD and fibrosis, supporting the therapeutic potential of p38 MAPK inhibitors such as SB 239063 in chronic airway disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Obstructive Pulmonary Disease
(2018) · Questions for the Final FFICM Structured Oral Examination · doi:10.1017/9781108233712.025 · Cited by 2,689
Inflammatory Mediators of Asthma: An Update
Barnes, P. J., Chung, K. F., & Page, C. P. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01381-4 · Cited by 717
Elias, J. A., Zhu, Z., Chupp, G., & Homer, R. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8124 · Cited by 702
Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One.
MacNee, W. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.3.8087359 · Cited by 488
Inhibition of p38 MAP kinase as a therapeutic strategy
Lee, J. C., Kumar, S., Griswold, D. E., Underwood, D. C., Votta, B. J., & Adams, J. L. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00206-x · Cited by 455
Self-citationHunninghake, G. W., & Crystal, R. G. (1983) · PubMed · doi:10.1164/arrd.1983.128.5.833 · Cited by 447
p38 Mitogen-Activated Protein Kinase Inhibitors— Mechanisms and Therapeutic Potentials
Lee, J. C., Kassis, S., Kumar, S., Badger, A., & Adams, J. L. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00008-x · Cited by 348
Self-citationThe Macrophage in Chronic Obstructive Pulmonary Disease
SHAPIRO, S. D. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.supplement_1.9 · Cited by 322
Underwood, D. C., Osborn, R. R., Kotzer, C. J., Adams, J. L., Lee, J. C., Webb, E. F., Carpenter, D. C., Bochnowicz, S., Thomas, H. C., Hay, D. W. P., et al. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39230-4 · Cited by 241
Self-citationSimon, C., Goepfert, H., & Boyd, D. (1998) · PubMed · Cited by 235
Cited by
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Neutrophils and acute lung injury
Abraham, E. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000057843.47705.e8 · Cited by 850
Cao, W., Daniel, K. W., Robidoux, J., Puigserver, P., Medvedev, A. V., Bai, X., Floering, L. M., Spiegelman, B. M., & Collins, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.3057-3067.2004 · Cited by 605
Metadata
- Authors
- Underwood, D. C., Osborn, R. R., Bochnowicz, S., Webb, E. F., Rieman, D. J., Lee, J. C., Romanic, A. M., Adams, J. L., Hay, D. W. P., & Griswold, D. E.
- Venue
- American Journal of Physiology-Lung Cellular and Molecular Physiology
- Publisher
- American Physiological Society
- Published
- 2000-11-01
- Volume
- 279
- Issue
- 5
- Pages
- L895-L902
- ISSN
- 1040-0605 (ISSN-L)
- 1522-1504
- OpenAlex
- W2181898446
- Cited by
- 297
- References
- 24
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. https://app.cochat.ai/papers/10.1152/ajplung.2000.279.5.l895
- The paper
- Underwood, D. C., Osborn, R. R., Bochnowicz, S., Webb, E. F., Rieman, D. J., Lee, J. C., Romanic, A. M., Adams, J. L., Hay, D. W. P., & Griswold, D. E. (2000). SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. American Journal of Physiology-Lung Cellular and Molecular Physiology. https://doi.org/10.1152/ajplung.2000.279.5.l895
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.